{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:19:19Z","timestamp":1791389959338,"version":"4.3.3"},"reference-count":21,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.neurol.2018.01.377","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T13:41:33Z","timestamp":1538660493000},"page":"65-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets"],"prefix":"10.1016","volume":"175","author":[{"given":"J.","family":"Bao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2018.01.377_bib0110","first-page":"1023","article-title":"The neuromuscular disorder in myasthenia gravis","volume":"14","author":"Desmedt","year":"2015","journal-title":"Oncology"},{"key":"10.1016\/j.neurol.2018.01.377_bib0115","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","article-title":"Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis","volume":"72","author":"Peeler","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2018.01.377_bib0120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jneuroim.2015.03.008","article-title":"Regulatory function of CD4+ CD25 ++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-dihydroxyvitamin D3 modulates the suppressor activity","volume":"281","author":"Alahgholi-Hajibehzad","year":"2015","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2018.01.377_bib0125","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/341758a0","article-title":"A receptor for the immunosuppressant FK506 is a cis-trans peptidyl","volume":"341","author":"Tanaka","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2018.01.377_bib0130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.gene.2013.10.034","article-title":"Differential expression of alternative splice variants of CTLA4 in Kuwaiti autoimmune disease patients","volume":"534","author":"AlFadhli","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.neurol.2018.01.377_bib0135","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.transproceed.2015.10.075","article-title":"Expression of endoplasmic reticulum-mediated stress proteins in FK506-treated T-lymphocytes","volume":"48","author":"Lee","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.neurol.2018.01.377_bib0140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis\u2014A randomized pilot study","volume":"53","author":"Nagane","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.neurol.2018.01.377_bib0145","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.377_bib0150","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","article-title":"FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.neurol.2018.01.377_bib0155","first-page":"989","article-title":"Regulatory function of tacrolimus and CsA on CD4\/CD8T lymphocyte subgroups and costimulators on them in allo-liver recipients","volume":"24","author":"Bai","year":"2008","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.neurol.2018.01.377_bib0160","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open-label pilot study","volume":"56","author":"Ciafaloni","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.377_bib0165","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.01.377_bib0170","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/ard.56.11.690","article-title":"Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases","volume":"56","author":"Duddridge","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.neurol.2018.01.377_bib0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000084648","article-title":"Management of severe refractory adult autoimmune enteropathy with infliximab and tacrolimus","volume":"71","author":"von Hahn","year":"2005","journal-title":"Digestion"},{"key":"10.1016\/j.neurol.2018.01.377_bib0180","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.neurol.2018.01.377_bib0185","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/jaut.1996.0111","article-title":"FK506 prevents induction of rat experimental autoimmune myasthenia gravis","volume":"10","author":"Yoshikawa","year":"1997","journal-title":"J Autoimmun"},{"key":"10.1016\/j.neurol.2018.01.377_bib0190","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0303-8467(03)00046-5","article-title":"Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis","volume":"106","author":"Wakata","year":"2003","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurol.2018.01.377_bib0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.clineuro.2004.07.013","article-title":"Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study","volume":"107","author":"Ponseti","year":"2005","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurol.2018.01.377_bib0200","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S1567-5769(01)00059-5","article-title":"Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system (Comparison with steroids)","volume":"1","author":"Sakuma","year":"2001","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.neurol.2018.01.377_bib0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-510X(97)00104-4","article-title":"Altered tumor growth factor beta mRNA expression is associated with thymectomy-related clinical remission in myasthenia gravis","volume":"151","author":"Weissert","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2018.01.377_bib0210","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.autrev.2005.01.007","article-title":"Regulatory T cells: development, function and role in autoimmunity","volume":"4","author":"Lan","year":"2005","journal-title":"Autoimmun Rev"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378717306240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378717306240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T13:08:23Z","timestamp":1551532103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378717306240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":21,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0035378717306240"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2018.01.377","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2018.01.377","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}